THRB
Thyroid hormone receptor beta
As of the edition of 20 October 2026, THRB (thyroid hormone receptor beta, UniProt P10828) has 9 drugs tested at it and 23 companies on the list, 1 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10828
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 34
- Disease areas
- Hormones; Nutrition and metabolism; Cancer; Digestive system; Heart and blood vessels; Nervous system; Urinary and reproductive; Inherited and neonatal
- Registered trials of its drugs
- 188
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Stopped | 3 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Levothyroxine | Marketed | Phase 4 | none listed |
| Liothyronine | Marketed | Phase 4 | none listed |
| Resmetirom | Marketed | Phase 4 | Ends 2033 |
| ASC41 | Stopped | Phase 2 | none listed |
| ALG-055009 | Active | Phase 2 | none listed |
| Eprotirome | Stopped | Phase 3 | none listed |
| Tiratricol | Marketed | Phase 3 | none listed |
| MB07811 | Stopped | Phase 2 | none listed |
| Dextrothyroxine | Marketed | Phase 3 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 4 |
| Engaged | 13 |
| Undetermined | 5 |
| Total on the list | 23 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| IBSA Institut Biochimique | Route B |
| ASKA Pharmaceutical | Route B |
The other 20 companies at THRB
In the product23 companies in all; 20 are not named here, and no score is.
See the 23 companies at THRB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.